Quantcast

EP Global Communications, Inc. Lands One of the World’s Leading Biomedical Engineers

September 24, 2012

David T. Markus Ph.D. to Join EPGL Med Team for Development of New Bio-MEMS Medical Devices

Irvine, CA (PRWEB) September 24, 2012

EP Global Communications, Inc. (the Company), (Pink Sheets: EPGL.PK) is pleased to announce that David T. Markus Ph.D. is joining the Company immediately and will oversee the research and development of the new EPGL Bio-Micro-Electro Mechanical Systems technology (Bio-MEMS). “Bio-MEMS is one of the fastest growing and promising new frontiers in medical technology today with possibilities in both medical diagnostic and treatment applications” said Company President, Michael Hayes. “The addition of David T. Markus Ph.D. to EPGL puts the Company on a new level and on the leading edge of new technology. This is a major league homerun for EPGL.” Dr. Markus joins Company Medical Director Corey W. Hunter M.D. and Eric Lee M.D.MA, who are both experts in the field of pain diagnosis and treatment. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.

About David T. Markus Ph.D.

David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus. spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world´s leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and “Ultraflexible Substrate” for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages. A full bio for Dr. Markus will be made available on the Company website in the near future.

Additional EPGL Med News

The Company will announce additional management members shortly and Board of Directors. The Company´s new website will come alive this week with information for physicians, patients and investors alike.

The second Company Q&A for investors will be held on Wednesday September, 26th on Twitter @epglmed. We encourage all investors to submit any questions to Brady Peterson, Company IR/PR Manager at investors(at)epglmed(dot)com.

About EP Global Communications, Inc.

EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.

Safe Harbor Statement

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company’s critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9934793.htm


Source: prweb



comments powered by Disqus